ClinicalTrials.govpublic full text
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
breast cancer, estrogen receptor negative breast cancer, biomarker studies, ki-67, dasatinib, bms-354825, sprycel, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 892233
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.